Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aprocitentan - Idorsia Pharmaceuticals

Next Previous
Drug Profile

Aprocitentan - Idorsia Pharmaceuticals

Alternative Names: AC 080; ACT-132577; JERAYGO; JNJ-2820; TRYVIO

Latest Information Update: 18 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Actelion Pharmaceuticals
  • Developer Idorsia Pharmaceuticals
  • Class Amides; Antihypertensives; Cardiovascular therapies; Ethers; Halogenated hydrocarbons; Pyrimidines; Small molecules
  • Mechanism of Action Endothelin A receptor antagonists; Endothelin B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypertension
  • Registered Resistant hypertension
  • Phase II Essential hypertension

Most Recent Events

  • 10 Nov 2025 Efficacy and adverse event data from a phase III PRECISION trial in Hypertension released by Idorsia Pharmaceuticals
  • 19 Sep 2025 Registered for Resistant hypertension (Combination therapy) in Switzerland (PO)
  • 09 Apr 2025 The US FDA approves an updated label for Aprocitentan (TRYVIO®) removing the REMS (Risk Evaluation and Mitigation Strategy) requirement

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top